COR NYSE Week ended 24 Jul 2026

Weekly Investor Report

Cencora Inc. · Healthcare · Medical Distribution

Open interactive chart View report data Download investor PDF
Latest close 309.9 USD
0.6% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is -2.2% below the Trend Line and sits at 49.8% of its 52-week range. The latest completed week returned 0.6%, after a 8.3% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is bullish with 57/100 conviction, while the latest news-sentiment score is 56/100. Near-term considerations: volume confirmation is below normal; earnings are due in 6d.

Setup score 43 out of 100
Latest Close 309.9 USD 24 Jul 2026
1W Return 0.6% latest completed week
4W Return 8.3% short-term follow-through
12W Return 2.2% quarterly tape
Trend Breadth 65.4% 34 of 52 weeks active
Volume Ratio 0.6x vs 13-week average
What is working
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 0.6% Latest completed week; four-week move 8.3%. Indicator stack 36/65 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Bullish 57/100 conviction; expected move 8.4%. News sentiment 56/100 37 relevant articles in the latest sentiment read. Event risk 6d Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -2.2% below the Trend Line and sits at 49.8% of its 52-week range. The latest completed week returned 0.6%, after a 8.3% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.1612-week average 0.17

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure2/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.16Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 8.3% over four weeks, 2.2% over 12 weeks, and 7.5% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W0.6%
4W8.3%
12W2.2%
26W-12.0%
52W7.5%
Active trend streak0 weeks
Active weeks in one year34
Trend breadth65.4%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.26Latest activity-pressure read.
Pressure change133.0%Four-week change in activity pressure.
Leadership-10.16Latest relative-leadership reading.
RS change39.3%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 30 Sep 2025 Field coverage 97% Model confidence 93%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength10/100Blend of value, momentum, and quality. Underlying universe rank 91; rank 1 is best.
Value27/100Relative valuation strength. Underlying universe rank 74; rank 1 is best.
Quality21/100Profitability and accounting quality. Underlying universe rank 80; rank 1 is best.
Momentum31/100Medium-term price momentum. Underlying universe rank 70; rank 1 is best.
Growth77/100Revenue and earnings growth. Underlying universe rank 24; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
23.7x
Price divided by trailing earnings.
Price / sales
0.2x
Market value relative to trailing revenue.
EV / EBITDA
14.1x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
4.2%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
3.5%
Gross profit retained from each unit of revenue.
Operating margin
1.2%
Operating profit retained from revenue.
Free-cash-flow margin
0.9%
Free cash flow generated from revenue.
Return on invested capital
21.3%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
5.9%
Latest one-year revenue growth.
EPS growth
50.5%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-35.5%
Latest one-year free-cash-flow growth.
Piotroski F-score
6/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
0.8%
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.8%
Dividend yield plus net buyback yield.
Net debt / EBITDA
2.0x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBullish

COR shows bullish options pressure with a 57/100 conviction score, put-call volume ratio of 0.04, expected move of 8.4%, and Sharemaestro trend signal inactive.

Conviction57/100
Expected move8.4%
Put/call volume0.04
Pressure100
Speculation39
Volatility61
Trend agreement0
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment56/100

Weighted news tone is neutral across 37 relevant articles.

13 positive · 21 neutral · 3 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings6dNext report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
Options expected move8.4%Nearest-chain priced movement where available.
52-week drawdown-17.6%Distance below the 52-week high.
13-week volatility5.0%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher15 of 2611 weeks finished lower.
Best week+6.7%Week of 22 May.
Worst week-14.1%Week of 8 May.
Latest week+0.6%Week of 24 Jul.

Shape of recent returns

Strong gains2
Modest gains13
Flat weeks0
Modest losses7
Sharp losses4
Recent vol5.0%13-week weekly-return volatility.
Base vol3.8%52-week weekly-return volatility.
Up/down split30/22Count of positive and negative weeks in the 52-week window.
Average skew2.5% / -3.0%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape39/100

Trend, activity pressure, participation, and risk combine to a 39/100 tape read.

 Indicator analysis15/100

Latest 12-week confirmation: trend 0/12, activity pressure 2/12, relative leadership 0/12.

Activity pressure 0.16; No reversal markers Factors20/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 63 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options50/100

COR shows bullish options pressure with a 57/100 conviction score, put-call volume ratio of 0.04, expected move of 8.4%, and Sharemaestro trend signal inactive.

Bullish · Call-side pressure · Expected move 8.4% Sentiment56/100

Weighted news tone is neutral across 37 relevant articles.

COR|Cencora Inc|Price:311.235|Chg%:+1.345 Insiders50/100

No recent insider transaction evidence is stored.

 Earnings6d

Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 2026309.9 USD0.6%316.9 USD260.6 USD0.26-10.165.6MOff
17 Jul 2026307.9 USD1.5%317.9 USD259.8 USD0.13-11.407.9MOff
10 Jul 2026303.4 USD2.3%318.9 USD259.0 USD-0.21-14.228.5MOff
3 Jul 2026296.5 USD3.6%320.3 USD258.3 USD-0.55-15.295.7MOff
26 Jun 2026286.1 USD5.3%321.7 USD257.6 USD-0.80-16.759.5MOff
19 Jun 2026271.8 USD-3.5%324.4 USD256.9 USD-1.02-23.097.7MOff
12 Jun 2026281.7 USD2.4%327.5 USD256.4 USD-1.04-20.005.2MOff
5 Jun 2026275.0 USD2.1%330.1 USD255.7 USD-0.97-21.817.5MOff
29 May 2026269.4 USD-2.0%332.9 USD255.1 USD-0.89-25.677.4MOff
22 May 2026274.9 USD6.7%335.1 USD254.4 USD-0.87-23.479.2MOff
15 May 2026257.7 USD-1.1%337.0 USD253.7 USD-0.85-28.0213.4MOff
8 May 2026260.5 USD-14.1%339.1 USD253.1 USD-0.88-27.5117.2MOff
1 May 2026303.3 USD-1.4%341.0 USD252.5 USD-0.96-14.116.8MOff
24 Apr 2026307.5 USD-5.9%340.9 USD251.6 USD-0.98-12.448.2MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.